Bristol Myers Squibb (BMY) announced today that it has agreed to acquire Karuna Therapeutics (KRTX), a biopharmaceutical company focused on psychiatric and neurological disorders, for $330 per share in cash, or $14 billion in total. “There are tremendous opportunities in neuroscience, and Karuna strengthens our position and accelerates the expansion and diversification of our portfolio…
All posts tagged Bristol Myers Squibb
Bristol Myers Squibb announces 5.3% dividend increase
PRINCETON: Bristol Myers Squibb (NYSE: BMY) announced that its Board of Directors has approved a quarterly dividend of $0.60 per share for the company’s common stock with a par value of $0.10. The dividend will be paid on February 1, 2024, to shareholders who own the stock as of the end of business on January…
Sensyne Health signs research collaboration agreement with Bristol Myers Squibb
OXFORD: Sensyne Health plc, the UK Clinical AI company, has signed a research collaboration agreement with Bristol Myers Squibb (BMS). Initially the collaboration will focus on applying Sensyne’s proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms (MPNs). MPNs comprise…
Bristol Myers Squibb completes acquisition of Forbius
NEW YORK: Bristol Myers Squibb has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis. “We are pleased to complete the transaction with Forbius and add their TGF-beta program to our growing pipeline of innovative assets,” said Rupert Vessey,…